Short- and Long-Term Outcomes of Mirikizumab for Ulcerative Colitis: A Real-World Multicenter Retrospective Cohort Study from the INSIGHT study - PubMed

5 hours ago

Mirikizumab (MIR), an IL-23p19 inhibitor, showed efficacy in treating ulcerative colitis (UC) in clinical trials.
A real-world study of 85 UC patients in Japan found clinical remission rates of 62.4% at week 12 and 55.3% at week 52.
CS-free remission rates matched overall remission rates at both 12 and 52 weeks.
Effectiveness was maintained regardless of prior exposure to biologics or JAK inhibitors.
Early clinical response at week 4 predicted remission at week 52, while steroid dependence predicted week 12 remission.
27.3% of initial nonresponders achieved remission by week 24 with extended induction.
Treatment was well tolerated, with 17.6% experiencing adverse events and 9.4% discontinuing due to adverse events.
No serious infections or hospitalizations were reported.

Hasty Briefsbeta